Latest & greatest articles for sumatriptan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sumatriptan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sumatriptan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sumatriptan

1. Sumatriptan

Sumatriptan Top results for sumatriptan - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sumatriptan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Bilateral Renal Infarctions During the Use of Sumatriptan

Bilateral Renal Infarctions During the Use of Sumatriptan 30197992 2018 11 14 2468-0249 3 5 2018 Sep Kidney international reports Kidney Int Rep Bilateral Renal Infarctions During the Use of Sumatriptan. 1233-1236 10.1016/j.ekir.2018.05.003 Abramovitz Blaise B Renal Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Leonberg-Yoo Amanda A Renal Electrolyte and Hypertension Division, Perelman School of Medicine

Kidney international reports2018 Full Text: Link to full Text with Trip Pro

3. Reduced efficacy of sumatriptan in migraine with aura vs without aura

Reduced efficacy of sumatriptan in migraine with aura vs without aura 25841032 2015 05 05 2015 07 13 2015 05 05 1526-632X 84 18 2015 May 05 Neurology Neurology Reduced efficacy of sumatriptan in migraine with aura vs without aura. 1880-5 10.1212/WNL.0000000000001535 To determine whether acute migraine treatment outcome is different in migraine with aura compared with migraine without aura. We examined pooled outcome data for sumatriptan treatment of migraine with and without aura from (...) the sumatriptan/naratriptan aggregate patient database. We also examined similar outcome data for inhaled dihydroergotamine (DHE) from a single, large randomized controlled study. The pooled pain-free rates 2 hours postdose for sumatriptan 100 mg were significantly higher in patients treating attacks without aura (32%) compared with the group who treated attacks with aura (24%) (p < 0.001). The relative risk for pain freedom 2 hours postdose for attacks without aura was 1.33 (95% confidence interval: 1.16

EvidenceUpdates2015

4. Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache?

Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2013

5. Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine

Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine 22585767 2012 06 04 2012 08 07 2013 11 21 1098-4275 129 6 2012 Jun Pediatrics Pediatrics Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. e1411-20 10.1542/peds.2011-2455 Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo (...) Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2012 05 14 United States Pediatrics 0376422 0031-4005 0 Placebos 57Y76R9ATQ Naproxen 8R78F6L9VO Sumatriptan AIM IM J Pediatr. 2012 Nov;161(5):969-70 23095698 Adolescent Child Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Humans Male Migraine Disorders drug therapy epidemiology pathology Naproxen administration & dosage Pain Measurement drug effects Placebos Single-Blind Method

EvidenceUpdates2012

6. WITHDRAWN: Oral sumatriptan for acute migraine.

WITHDRAWN: Oral sumatriptan for acute migraine. BACKGROUND: Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition (...) . OBJECTIVES: To describe and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books. SELECTION CRITERIA: We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg

Cochrane2012

7. Sumatriptan Galpharm

Sumatriptan Galpharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged London, 23 November 2011 EMA/40740/2012 Assessment Report Sumatriptan Galpharm 50 mg Tablets International non proprietary name: sumatriptan Procedure No. EMEA/H/C (...) /002140 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Sumatriptan 50 mg Tablets Perrigo Assessment Report EMA/40740/2012 Page 2/43 Table of contents 1 3 Background information on the procedure 1.1 3 Submission of the dossier 1.2 5 Steps taken for the re-examination of the product 2 5 Scientific discussion 2.1 5 Introduction 2.2 6 Quality aspects 2.3 10 Non- Clinical aspects 2.4 11 Clinical Aspects 2.5 21 Pharmacovigilance 3 25 Benefit-Risk

European Medicines Agency - EPARs2012

8. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan

Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan 20303198 2010 07 12 2010 08 05 2016 11 22 1097-6760 56 1 2010 Jul Annals of emergency medicine Ann Emerg Med Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. 7-17 10.1016/j.annemergmed.2010.02.005 Multiple parenteral medications are used to treat migraine and other acute primary headaches (...) in the emergency department (ED). Regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of primary headache after ED discharge. It is uncertain which medication primary headache patients should be given on discharge from an ED. The aim of this study is to compare the efficacy of oral sumatriptan with naproxen for treatment of post-ED recurrent primary headache. This was a randomized, double-blind efficacy trial. We randomized patients to either naproxen 500

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

9. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department

A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department 20045576 2010 07 12 2010 08 05 2014 11 20 1097-6760 56 1 2010 Jul Annals of emergency medicine Ann Emerg Med A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. 1-6 10.1016/j.annemergmed.2009.11.020 Intravenous (IV) prochlorperazine (...) with diphenhydramine is superior to subcutaneous sumatriptan in the treatment of migraine patients presenting to the emergency department (ED). In this randomized, double-blind, placebo-controlled trial, after providing written informed consent, patients presenting to the ED with a chief complaint of migraine received a 500-mL bolus of IV saline solution and either 10 mg prochlorperazine with 12.5 mg diphenhydramine IV plus saline solution placebo subcutaneously or saline solution placebo IV plus 6 mg sumatriptan

EvidenceUpdates2010

10. Alsuma (sumatriptan) injection

Alsuma (sumatriptan) injection Drug Approval Package: Alsuma (sumatriptan) NDA #022377 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Alsuma (sumatriptan) 6mg/0.5ml injection Company: King Pharmaceuticals, Inc. Application No.: 022377 Approval Date: 06/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2010

11. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life 19486178 2009 07 08 2009 10 08 2013 11 21 1526-4610 49 7 2009 Jul Headache Headache Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. 971-82 10.1111/j.1526-4610.2009.01458.x To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued (...) treatment with a short-acting triptan because of poor response or intolerance. Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting

EvidenceUpdates2009

12. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine 18606965 2008 07 08 2008 07 22 2013 11 21 1526-632X 71 2 2008 Jul 08 Neurology Neurology Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. 114-21 10.1212/01.wnl.0000316800.22949.20 Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome. To investigate the efficacy and tolerability of a fixed (...) -dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine. Patients (aged 18 to 65 years) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while

EvidenceUpdates2008

13. Treximet (sumatriptan and naproxen sodium)

Treximet (sumatriptan and naproxen sodium) Drug Approval Package: Treximet (sumatriptan and naproxen sodium) NDA #021926 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Treximet (sumatriptan and naproxen sodium) Tablets Company: Pozen Inc. Application No.: 021926 Approval Date: 04/15/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s

FDA - Drug Approval Package2008

14. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. 17405970 2007 04 04 2007 04 06 2016 10 17 1538-3598 297 13 2007 Apr 04 JAMA JAMA Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. 1443-54 Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy. To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate (...) and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine. Two replicate, randomized, double-blind, single-attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack. Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen

JAMA2007

15. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine

Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Zhang L, Hay J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three technologies for the treatment of migraine were studied. These were rizatriptan 10 mg, sumatriptan 50 mg, and a fixed-dose combination of ergotamine tartrate plus caffeine (Cafergot) 2 mg/200 mg. Cafergot was used as the comparator. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2005

16. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point

A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point Williams P, Reeder C E Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of almotriptan 12.5 mg versus two dosing levels of sumatriptan (50 mg and 100 mg) for the treatment of an acute migraine attack. Type of intervention Treatment. Economic study type

NHS Economic Evaluation Database.2004

18. Imitrex (Sumatriptan)

Imitrex (Sumatriptan) Drug Approval Package: Imitrex (Sumatriptan) NDA #020132s015 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Imitrex (Sumatriptan) Tablets Company: GlaxoSmithKline Application No.: 020132s015 Approval Date: 06/30/2003 (PDF) (PDF) (PDF) (PDF) (PDF) Date created: May 052006 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats, see . Language

FDA - Drug Approval Package2003

19. Costs and outcomes of early versus delayed migraine treatment with sumatriptan

Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Halpern M T, Lipton R B, Cady R K, Kwong W J, Marlo K O, Batenhorst A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of early sumatriptan treatment for mild migraine versus delayed sumatriptan treatment for moderate to severe migraine. Doses of 50 mg or 100 mg were considered for both treatments. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients experiencing mild migraine

NHS Economic Evaluation Database.2002

20. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis

Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis Caro G, Getsios D, Caro J J, Raggio G, Burrows M, Black L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sumatriptan in the treatment of patients with migraine. Six alternative strategies with sumatriptan were analysed: subcutaneous sumatriptan, 6mg; oral sumatriptan, 100 mg; oral sumatriptan, 50 mg; sumatriptan nasal spray, 10 mg; sumatriptan nasal spray, 20 mg; sumatriptan

NHS Economic Evaluation Database.2001